OGN, osteoglycin, 4969

N. diseases: 55; N. variants: 0
Source: ALL
Disease Score gda Association Type Type Original DB Sentence supporting the association PMID PMID Year
CUI: C0004153
Disease: Atherosclerosis
Atherosclerosis 		0.020 Biomarker disease BEFREE However, the role of osteoglycin in atherosclerosis remains unclear. 29503411 2018
CUI: C0006826
Disease: Malignant Neoplasms
Malignant Neoplasms 		0.020 AlteredExpression group BEFREE Consistently, immunofluorescence validated that OGN was preferentially expressed with CD8+ cells in both normal epithelium and cancer tissue. 30037719 2018
CUI: C0011847
Disease: Diabetes
Diabetes 		0.020 Biomarker disease BEFREE Besides carotid artery plaque, lumican was related to impaired glucose tolerance (r = 0.162, p = 0.046) and adversely related to osteoglycin (r = - 0.273, p < 0.001), whereas unrelated to age, sex, BMI, diabetes, blood pressure, serum lipids, high-sensitivity C-reactive protein, or carotid intima-media thickness in univariate correlation analyses. 29867136 2018
CUI: C0011849
Disease: Diabetes Mellitus
Diabetes Mellitus 		0.020 Biomarker group BEFREE Besides carotid artery plaque, lumican was related to impaired glucose tolerance (r = 0.162, p = 0.046) and adversely related to osteoglycin (r = - 0.273, p < 0.001), whereas unrelated to age, sex, BMI, diabetes, blood pressure, serum lipids, high-sensitivity C-reactive protein, or carotid intima-media thickness in univariate correlation analyses. 29867136 2018
CUI: C1306459
Disease: Primary malignant neoplasm
Primary malignant neoplasm 		0.020 AlteredExpression group BEFREE Consistently, immunofluorescence validated that OGN was preferentially expressed with CD8+ cells in both normal epithelium and cancer tissue. 30037719 2018
CUI: C0007222
Disease: Cardiovascular Diseases
Cardiovascular Diseases 		0.020 Biomarker group BEFREE Osteoglycin (OGN) has been noted for its implication in cardiovascular disease in recent studies. 28069703 2017
CUI: C0003507
Disease: Aortic Valve Stenosis
Aortic Valve Stenosis 		0.020 Biomarker disease BEFREE Taken together, these data implicate Ogn as a key regulator of LVM in rats, mice and humans, and suggest that Ogn modifies the hypertrophic response to extrinsic factors such as hypertension and aortic stenosis. 18443592 2008
CUI: C0006826
Disease: Malignant Neoplasms
Malignant Neoplasms 		0.020 AlteredExpression group BEFREE All adenoma and cancer tissues did not express mimecan, but all normal mucosa did (P < 0.01). 17895523 2007
CUI: C1302401
Disease: Adenoma of large intestine
Adenoma of large intestine 		0.020 AlteredExpression disease BEFREE Differential expression of mimecan and thioredoxin domain-containing protein 5 in colorectal adenoma and cancer: a proteomic study. 17895523 2007
CUI: C1306459
Disease: Primary malignant neoplasm
Primary malignant neoplasm 		0.020 AlteredExpression group BEFREE All adenoma and cancer tissues did not express mimecan, but all normal mucosa did (P < 0.01). 17895523 2007
CUI: C0004604
Disease: Back Pain
Back Pain 		0.010 Biomarker phenotype BEFREE Results of fully adjusted logistic regression models revealed that OIF/OEF women in Puerto Rico had heightened risk for global pain-related disorders (i.e., any pain) (adjusted odds ratio [AOR], 1.45; 95% confidence interval [CI], 1.22-1.71), back pain (AOR, 1.83; 95% CI, 1.56-2.14), diabetes (AOR, 1.42; 95% CI, 1.03-1.95), hyperlipidemia (AOR, 3.34; 95% CI, 2.80-3.98), major depression (AOR, 1.78; 95% CI, 1.53-2.06), and bipolar depression (AOR, 1.66; 95% CI, 1.34-2.04). 31796346 2019
CUI: C0006142
Disease: Malignant neoplasm of breast
Malignant neoplasm of breast 		0.010 AlteredExpression disease BEFREE OGN expression was reduced in 24 paired BC samples compared with normal tissue. 31824171 2019
CUI: C0020473
Disease: Hyperlipidemia
Hyperlipidemia 		0.010 Biomarker disease BEFREE Results of fully adjusted logistic regression models revealed that OIF/OEF women in Puerto Rico had heightened risk for global pain-related disorders (i.e., any pain) (adjusted odds ratio [AOR], 1.45; 95% confidence interval [CI], 1.22-1.71), back pain (AOR, 1.83; 95% CI, 1.56-2.14), diabetes (AOR, 1.42; 95% CI, 1.03-1.95), hyperlipidemia (AOR, 3.34; 95% CI, 2.80-3.98), major depression (AOR, 1.78; 95% CI, 1.53-2.06), and bipolar depression (AOR, 1.66; 95% CI, 1.34-2.04). 31796346 2019
CUI: C0030193
Disease: Pain
Pain 		0.010 Biomarker phenotype BEFREE Results of fully adjusted logistic regression models revealed that OIF/OEF women in Puerto Rico had heightened risk for global pain-related disorders (i.e., any pain) (adjusted odds ratio [AOR], 1.45; 95% confidence interval [CI], 1.22-1.71), back pain (AOR, 1.83; 95% CI, 1.56-2.14), diabetes (AOR, 1.42; 95% CI, 1.03-1.95), hyperlipidemia (AOR, 3.34; 95% CI, 2.80-3.98), major depression (AOR, 1.78; 95% CI, 1.53-2.06), and bipolar depression (AOR, 1.66; 95% CI, 1.34-2.04). 31796346 2019
CUI: C0041696
Disease: Unipolar Depression
Unipolar Depression 		0.010 GeneticVariation disease BEFREE Results of fully adjusted logistic regression models revealed that OIF/OEF women in Puerto Rico had heightened risk for global pain-related disorders (i.e., any pain) (adjusted odds ratio [AOR], 1.45; 95% confidence interval [CI], 1.22-1.71), back pain (AOR, 1.83; 95% CI, 1.56-2.14), diabetes (AOR, 1.42; 95% CI, 1.03-1.95), hyperlipidemia (AOR, 3.34; 95% CI, 2.80-3.98), major depression (AOR, 1.78; 95% CI, 1.53-2.06), and bipolar depression (AOR, 1.66; 95% CI, 1.34-2.04). 31796346 2019
CUI: C0302592
Disease: Cervix carcinoma
Cervix carcinoma 		0.010 AlteredExpression disease BEFREE Previous studies have indicated that the small leucine-rich proteoglycan (SLR) osteoglycin (OGN) is downregulated in various cancers, including squamous cervical carcinoma, gastric cancer, and colorectal adenoma, indicating that OGN is a putative tumor suppressor. 31824171 2019
CUI: C0678222
Disease: Breast Carcinoma
Breast Carcinoma 		0.010 AlteredExpression disease BEFREE OGN expression was reduced in 24 paired BC samples compared with normal tissue. 31824171 2019
CUI: C1269683
Disease: Major Depressive Disorder
Major Depressive Disorder 		0.010 GeneticVariation disease BEFREE Results of fully adjusted logistic regression models revealed that OIF/OEF women in Puerto Rico had heightened risk for global pain-related disorders (i.e., any pain) (adjusted odds ratio [AOR], 1.45; 95% confidence interval [CI], 1.22-1.71), back pain (AOR, 1.83; 95% CI, 1.56-2.14), diabetes (AOR, 1.42; 95% CI, 1.03-1.95), hyperlipidemia (AOR, 3.34; 95% CI, 2.80-3.98), major depression (AOR, 1.78; 95% CI, 1.53-2.06), and bipolar depression (AOR, 1.66; 95% CI, 1.34-2.04). 31796346 2019
CUI: C0011881
Disease: Diabetic Nephropathy
Diabetic Nephropathy 		0.010 Biomarker disease BEFREE OIF <343.4 pg/mL remained predictive of microalbuminuria (odds ratio = 11.60; 95% confidence interval: 1.25-107.47) after adjusting for confounding factors.Serum OIF is an independent diagnostic marker of DN. 30075597 2018
CUI: C0085580
Disease: Essential Hypertension
Essential Hypertension 		0.010 Biomarker disease BEFREE The present study investigated the relationship between carotid atherosclerosis plaque and the circulating levels of some SLRPs, including decorin, lumican, and osteoglycin, in essential hypertension. 29867136 2018
CUI: C0152105
Disease: Hypertensive heart disease
Hypertensive heart disease 		0.010 Biomarker disease BEFREE However, whether osteoglycin modulates cardiac hypertrophy, fibrosis or inflammation in hypertensive heart disease and during aging remains unknown. 28958774 2018
CUI: C0178874
Disease: Tumor Progression
Tumor Progression 		0.010 AlteredExpression phenotype BEFREE As results, in vitro and in vivo, the OGN expression was demonstrated to reduce cell proliferation, inhibit invasion of colon cancer cells then impede cancer progression. 29499765 2018
CUI: C0271650
Disease: Impaired glucose tolerance
Impaired glucose tolerance 		0.010 Biomarker phenotype BEFREE Besides carotid artery plaque, lumican was related to impaired glucose tolerance (r = 0.162, p = 0.046) and adversely related to osteoglycin (r = - 0.273, p < 0.001), whereas unrelated to age, sex, BMI, diabetes, blood pressure, serum lipids, high-sensitivity C-reactive protein, or carotid intima-media thickness in univariate correlation analyses. 29867136 2018
CUI: C0596263
Disease: Carcinogenesis
Carcinogenesis 		0.010 Biomarker phenotype BEFREE The effect of OGN on cell proliferation and tumorigenesis was examined in vitro and in vivo. 29499765 2018
CUI: C1397307
Disease: Cardiac fibrosis
Cardiac fibrosis 		0.010 Biomarker disease BEFREE Osteoglycin prevents the development of age-related diastolic dysfunction during pressure overload by reducing cardiac fibrosis and inflammation. 28958774 2018